区域化铜驱动的乳腺癌进展被铜削减纳米剂用于免疫和代谢重编程所抵制
Lin Chen1,2, Saibo Ma1,3, Hao Wu1
1CAS Key Laboratory for Biomedical Effects of Nanomaterials & Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing, 100190, China.
Advanced science (Weinheim, Baden-Wurttemberg, Germany)
|April 24, 2025
概括
乳腺癌瘤中铜的升高促进了生长和转移. 一种新的纳米剂消耗铜,重编程新陈代谢并恢复抗瘤免疫力,在临床前模型中显示出有前途.
科学领域:
- 在瘤学瘤学.
- 金属的新陈代谢
- 纳米医学是一种纳米医学.
背景情况:
- 在癌症中观察到异常的金属代谢,但瘤中的空间积累和调节影响不明.
- 铜的失调与癌症有关,但它在乳腺癌病理生理学和免疫规避中的特定作用需要进一步阐明.
研究的目的:
- 研究铜积累在乳腺癌中的空间分布和功能影响.
- 开发和评估一种用于乳腺瘤中铜耗尽的新型纳米剂.
- 探索针对铜代谢治疗乳腺癌的治疗潜力.
主要方法:
- 用空间分辨的多组学分析来描述铜的区域化及其在乳腺癌中的代谢后果.
- 一种基于细菌外膜囊泡 (hOMV) 的混合细菌纳米剂 (TM@CD326hOMV) 已被设计用于有针对性的铜耗尽.
- 在小鼠乳腺癌模型中评估治疗疗效,评估瘤生长,转移,免疫反应和存活率.
主要成果:
- 升高的铜水平在乳腺瘤中表现出区域空间模式,促进氧化酸化 (OXPHOS) 超过糖解,并促进免疫沙漠表型.
- 系统的TM@CD326hOMV有效地降低了瘤铜水平,抑制了瘤生长和转移,并重新编程了新陈代谢向糖解.
- 该纳米剂恢复了抗瘤免疫力,并使用TM@CD326hOMV和检查点阻塞的联合治疗与单一疗法相比显示出更高的疗效.
结论:
- 铜区划显著影响乳腺癌病理生理学,驱动特定的代谢偏好和免疫逃避.
- 开发的消耗铜的纳米剂 (TM@CD326hOMV) 通过向瘤代谢和增强抗瘤免疫力,显示出显著的治疗潜力.
- 准铜代谢是乳腺癌治疗的有希望的策略,有可能用于组合疗法.
相关概念视频
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Metastasis
5.4K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.4K


